Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy (LHON)

Next Previous
Trial Profile

A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy (LHON)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Leber's hereditary optic atrophy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ReSIGHT
  • Sponsors Stealth BioTherapeutics

Most Recent Events

  • 24 Jan 2020 Status changed from active, no longer recruiting to completed.
  • 14 Aug 2019 According to a Stealth BioTherapeutics media release, data from the trial and open label extension phase was presented at the United Mitochondrial Disease Foundation Symposium 2019 and at the 14th meeting of the European Neuro-ophthalmology Society.
  • 30 Apr 2019 According to a Stealth BioTherapeutics media release, results from the study were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top